Second, because they act downstream of p53 (Figure 1b), even the vast majority of tumours with a defective p53 pathway remain vulnerable.90 Third, the oncologist can focus therapy on the pro-survival target(s) to which a particular tumour is ‘addicted’. Here, TP53 is linked to neoplasm.